NECTIN4 and neoplasm: Both drugs use TLR8 agonists as payloads, with the difference that SBT6050 targets HER2 and SBT6290 targets Nectin4 (Nectin cell adhesion molecule 4, a type I membrane protein that is overexpressed in a variety of tumor cells).